Severe Skin Toxicity and Early Progression Following Neoadjuvant Ensartinib and Surgery in Anaplastic Lymphoma Kinase-positive Locally Advanced Lung Cancer: A Case Report

Hongming Wang¹Shiyan Li¹Zhijun Wu¹Wei Xu²Nuoni Wang^3*Zemin Xiao^1*

• ¹Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University, The First People’s Hospital of Changde City, Changde, China
• ²Department of Thoracic Surgery, Changde Hospital, Xiangya School of Medicine, Central South University, The First People’s Hospital of Changde City, Changde, China
• ³Department of Electrophysiology, Changde Hospital, Xiangya School of Medicine, Central South University, The First People’s Hospital of Changde City, Changde, China

Background: Anaplastic lymphoma kinase (ALK) fusion mutations exhibit exceptional sensitivity to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). Ensartinib, a second-generation ALK-TKI, represents a promising therapeutic option for ALK mutation-associated NSCLC; however, its clinical application in perioperative therapy remains to be elucidated. Case description: We report the case of a 45-year-old female diagnosed with stage IIIA (cT2N2M0, AJCC eighth edition) adenocarcinoma of the right lung harboring an EML4-ALK fusion (E6:A20) and a TP53 mutation. Following 3-month neoadjuvant therapy with ensartinib, surgical conversion from R(un) to R0 resection was achieved, accompanied by histopathological assessment and confirmation of a major pathological response (MPR) (<10% viable tumor cells) and negative postoperative molecular residual disease (MRD) surveillance. Despite effective neoadjuvant targeted therapy and the absence of significant adverse events, the patient experienced drug-refractory grade 3 cutaneous toxicity (CTCAE v5.0) 4 weeks after surgery and was subsequently found to have a T12 vertebral metastasis on 3‑month surveillance imaging. After multidisciplinary evaluation and considering the patient's refusal to undergo local therapies, treatment was switched to lorlatinib. The patient subsequently experienced complete resolution of skin toxicity, sustained disease control, and a significantly improved quality of life. Conclusions: This case report describes a patient with an MPR subsequent to neoadjuvant ensartinib, who nonetheless developed early postoperative progression. Our case cautions that although MPR and MRD negativity can strongly predict lower recurrence risk, these markers may not universally guarantee long-term remission in every individual. The case underscores the need for continued vigilance and individualized surveillance strategies even once favorable pathological responses are achieved. Additionally, the perioperative evolution of skin toxicity highlights the importance of continuous adverse event monitoring and management.